BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”) announced today that Horizon Medical Services (Horizon) in Tamarac, Florida has purchased a BSD-500 Hyperthermia System (BSD-500). Horizon is a sophisticated, freestanding, mobile radiation therapy center that offers technologically advanced cancer care in the South Florida area. Horizon has offices in Miami and in Coral Springs. Horizon's mobile radiation therapy units provide treatments throughout Southern Florida. The purchase of the BSD-500 by Horizon increases the number of patients who will have access to innovative hyperthermia treatment. This sale is further evidence of the growing use of hyperthermia therapy in Florida and in the United States. “Clinical studies have shown that hyperthermia delivered using the BSD-500 can significantly increase the effectiveness of radiation therapy without a significant increase in toxicity for certain tumors. We are excited to have a BSD hyperthermia system placed in the prestigious Horizon Medical Services facility,” stated Harold Wolcott, BSD's President. About the BSD-500 Hyperthermia System The BSD-500 Hyperthermia System is used to deliver therapeutic heating (hyperthermia) using either non-invasive (external) hyperthermia, which is delivered using antennas placed over the tumor, or interstitial hyperthermia, which is delivered using antennas that are inserted into the tumor, or a combination of both. The BSD-500 has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the use of hyperthermia in conjunction with radiation therapy to treat certain tumors. About BSD Medical Corporation BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com. Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.